


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(Currently Amended)** A compound of formula (I)



wherein ring A represents a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group of methyl, ethyl, a fluorine atom, a chlorine atom, methoxy, ethoxy,[[,]] and acetyl[[,]];

ring B represents a benzene ring which may have a substituent(s), a thiophene ring which may have a substituent(s), an indan ring which may have a substituent(s), or a 1,3-benzodioxole ring which may have a substituent(s),[[,]] wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of a fluorine atom, and a chlorine atom;

K represents C1-4 alkylene;

Q represents methylene, or ethylene;

M represents a bond, C1-4 alkylene which may have a substituent(s), or C2-4 alkenylene which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) of methyl;

ring D represents a benzene ring which may have a substituent(s), a pyrrole ring which may have a substituent(s), a pyrazole ring which may have a substituent(s), or a thiazole ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of, methyl, and methoxycarbonyl[L, I];

ring E represents a benzene ring;


L represents a bond, or $-O-$;


Z represents COOH , $\text{CONHSO}_2\text{R}^1$, in which R^1 represents methyl, or, a benzene ring which may have a substituent(s), wherein the substituent(s) is 1 to 5 optional substituent(s) selected from the group consisting of methyl; and

t represents 0 or 1, or

a salt thereof.

2. (Original) The compound according to claim 1, wherein the compound of formula (I) is an optically active compound of formula (I-A):



wherein  represents β -configuration; and other symbols have the same meanings as described in claim 1.

3.-4. (Canceled)

5. **(Previously presented)** The compound according to claim 1, wherein ring B is an indan ring which may have a substituent(s).

6. **(Canceled)**

7. **(Original)** The compound according to claim 1, wherein ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s).

8. **(Canceled)**


9. **(Original)** The compound according to claim 1, wherein



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted.

10. **(Previously presented)** The compound according to claim 1, wherein ring A is a benzene ring which may have a substituent(s); ring B is an indan ring which may have a substituent(s);

ring D is a benzene ring which may have a substituent(s), a pyrazole ring which may have a substituent(s) or a pyrrole ring which may have a substituent(s);



is methylene which may be substituted, ethylene which may be substituted, propylene which may be substituted, or ethenylene which may be substituted; and

Z is -COOH; -CONHSO₂R¹, in which R¹ is methyl, a benzene ring which may have a substituent(s).

11. **(Original)** The compound according to claim 1, which is selected from the group consisting of:

- (1) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (2) (1-{(2S)-2-[(S)-(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-thien-3-ylpentyl}-1H-pyrrol-3-yl)acetic acid,
- (3) {1-[(2S,3S)-2-(1,3-benzodioxol-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (4) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}acetic acid,
- (5) {1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,

- (6) {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acetic acid,
- (7) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,
- (8) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxy-3-(3,4,5-trimethoxyphenyl)propyl]-1H-pyrrol-3-yl}propanoic acid,
- (9) 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,
- (10) 3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(4-ethyl-3,5-dimethoxyphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoic acid,
- (11) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}-N-(methylsulfonyl)acetamide,
- (12) [1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-4-(methoxycarbonyl)-1H-pyrrol-3-yl]acetic acid,
- (13) N-(3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}propanoyl)-2-methylbenzenesulfonamide,
- (14) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}acrylic acid,
- (15) 2-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}-2-methylpropanoic acid, and
- (16) (2E)-3-{1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-1H-pyrrol-3-yl}-2-methylacrylic acid.

12. **(Previously presented)** A pharmaceutical composition comprising the compound of formula (I) according to claim 1, or a salt thereof.

13. **(Original)** The pharmaceutical composition according to claim 12, which is an LPA receptor antagonist, wherein the LPA receptor is EDG-2.

14. **(Canceled)**

15. **(Original)** The pharmaceutical composition according to claim 12, which is an agent for prevention and/or treatment for urinary system disease.

16. **(Previously presented)** A method for treatment of urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia, which comprises administering to a mammal an effective amount of the compound of formula (I) according to claim 1, or a salt thereof.

17. **(Canceled)**

18. **(Previously presented)** A pharmaceutical composition comprising a combination of the compound of formula (I) according to claim 1, or a salt thereof with at least one agent selected from an LPA receptor antagonist, an $\alpha 1$ blocking agent, an anticholinergic agent, a 5α -reductase inhibitor and an anti-androgenic agent.